|
1
|
de Jong WK, Blaauwgeers JL, Schaapveld M,
Timens W, Klinkenberg TJ and Groen HJ: Thymic epithelial tumours: A
population-based study of the incidence, diagnostic procedures and
therapy. Eur J Cancer. 44:123–130. 2008.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Mariusdottir E, Nikulasson S, Bjornsson J
and Gudbjartsson T: Thymic epithelial tumours in iceland: Incidence
and histopathology, a population-based study. APMIS. 118:927–933.
2010.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Gadalla SM, Rajan A, Pfeiffer R,
Kristinsson SY, Bjorkholm M, Landgren O and Giaccone G: A
population-based assessment of mortality and morbidity patterns
among patients with thymoma. Int J Cancer. 128:2688–2694.
2011.PubMed/NCBI View Article : Google Scholar
|
|
4
|
National Comprehensive Cancer Network
(NCCN): Thymomas and Thymic Carcinomas. Version 2.2016. NCCN,
Plymouth Meeting, PA, 2016. https://thymicuk.org/wp-content/uploads/2019/10/NCCN-Thymoma-and-Thymic-cancer-guidelines.pdf.
Accessed March 16, 2016.
|
|
5
|
Engels EA: Epidemiology of thymoma and
associated malignancies. J Thorac Oncol. 5 (10 Suppl 4):S260–S265.
2010.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Strollo DC, Rosado de Christenson ML and
Jett JR: Primary mediastinal tumors. Part 1: Tumors of the anterior
mediastinum. Chest. 112:511–522. 1997.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Engels EA and Pfeiffer RM: Malignant
thymoma in the United States: Demographic patterns in incidence and
associations with subsequent malignancies. Int J Cancer.
105:546–551. 2003.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Gradishar WJ: Albumin-bound paclitaxel: A
next-generation taxane. Expert Opin Pharmacother. 7:1041–1053.
2006.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Gradishar WJ, Tjulandin S, Davidson N,
Shaw H, Desai N, Bhar P, Hawkins M and O'Shaughnessy J: Phase III
trial of nanoparticle albumin-bound paclitaxel compared with
polyethylated castor oil-based paclitaxel in women with breast
cancer. J Clin Oncol. 23:7794–7803. 2005.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Socinski MA, Bondarenko I, Karaseva NA,
Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P,
Zhang H, et al: Weekly nab-paclitaxel in combination with
carboplatin versus solvent-based paclitaxel plus carboplatin as
first-line therapy in patients with advanced non-small-cell lung
cancer: Final results of a phase III trial. J Clin Oncol.
30:2055–2062. 2012.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Hirsh V, Okamoto I, Hon JK, Page RD,
Orsini J, Sakai H, Zhang H, Renschler MF and Socinski MA:
Patient-reported neuropathy and taxane-associated symptoms in a
phase 3 trial of nab-paclitaxel plus carboplatin versus
solvent-based paclitaxel plus carboplatin for advanced
non-small-cell lung cancer. J Thorac Oncol. 9:83–90.
2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Koizumi W, Morita S and Sakata Y: A
randomized phase III trial of weekly or 3-weekly doses of
nab-paclitaxel versus weekly doses of cremophor-based paclitaxel in
patients with previously treated advanced gastric cancer (ABSOLUTE
trial). Jpn J Clin Oncol. 45:303–306. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Shitara K, Takashima A, Fujitani K, Koeda
K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Makari Y, Amagai K,
et al: Nab-paclitaxel versus solvent-based paclitaxel in patients
with previously treated advanced gastric cancer (ABSOLUTE): An
open-label, randomised, non-inferiority, phase 3 trial. Lancet
Gastroenterol Hepatol. 2:277–287. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Travis WD, Brambilla E, Burke AP, Marx A
and Nicolson AG: Introduction to The 2015 World health organization
classification of tumors of the lung, Pleura, thymus, and heart. J
Thorac Oncol. 10:1240–1242. 2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Masaoka A, Monden Y, Nakahara K and
Tanioka T: Follow-up study of thymomas with special reference to
their clinical stages. Cancer. 48:2485–2492. 1981.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). J Eur J Cancer. 45:228–247.
2009.PubMed/NCBI View Article : Google Scholar
|
|
17
|
U.S. Department of Health and Human
Services, National Institutes of Health and National Cancer
Institute: Common Terminology Criteria for Adverse Events (CTCAE).
Version 4.0. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf.
Accessed May 28, 2009.
|
|
18
|
Lemma GL, Lee JW, Aisner SC, Langer CJ,
Tester WJ, Johnson DH and Loehrer PJ Sr: Phase II study of
carboplatin and paclitaxel in advanced thymoma and thymic
carcinoma. J Clin Oncol. 29:2060–2065. 2011.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Makimoto G, Fujiwara K, Watanabe H,
Kameyama N, Matsushita M, Rai K, Sato K, Yonei T, Sato T and
Shibayama T: nab-paclitaxel in combination with carboplatin for a
previously treated thymic carcinoma. Case Rep Oncol. 7:14–17.
2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Igawa S, Yanagisawa N, Niwa H, Ishihara M,
Hiyoshi Y, Otani S, Katono K, Sasaki J, Satoh Y and Masuda N:
Successful chemotherapy with carboplatin and nab-paclitaxel for
thymic large cell neuroendocrine carcinoma: A case report. Oncol
Lett. 10:3519–3522. 2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhan P, Xie H and Yu LK: Response to
nab-paclitaxel and nedaplatin in a heavily-metastatic thymic
carcinoma: A case report. Oncol Lett. 9:1715–1718. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Shima H, Ozasa H, Tsuji T, Ajimizu H,
Nomizo T, Yagi Y, Sakamori Y, Nagai H, Minamiguchi S, Kim YH and
Mishima M: Response to chemotherapy with carboplatin plus
albumin-bound paclitaxel in a patient with lymphoepithelioma-like
thymic carcinoma: A case report. Mol Clin Oncol. 4:715–718.
2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Funaishi K, Yamasaki M, Saito N, Daido W,
Ishiyama S, Deguchi N, Taniwaki M and Ohashi N: First-line
treatment with carboplatin plus nab-paclitaxel and maintenance
monotherapy with nab-paclitaxel for a thymic carcinoma: A case
report. Case Rep Oncol. 10:571–576. 2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Ley J, Wildes TM, Daly K, Oppelt P and
Adkins D: Clinical benefit of nanoparticle albumin-bound-paclitaxel
in recurrent/metastatic head and neck squamous cell carcinoma
resistant to cremophor-based paclitaxel or docetaxel. Med Oncol.
34(28)2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Maurer K, Michener C, Mahdi H and Rose PG:
Universal tolerance of nab-paclitaxel for gynecologic malignancies
in patients with prior taxane hypersensitivity reactions. J Gynecol
Oncol. 28(e38)2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Sato J, Satouchi M, Itoh S, Okuma Y, Niho
S, Mizugaki H, Murakami H, Fujisaka Y, Kozuki T, Nakamura K, et al:
Lenvatinib in patients with advanced or metastatic thymic carcinoma
(REMORA): A multicentre, phase 2 trial. Lancet Oncol. 21:843–850.
2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Gong W, Sun P, Mu Z, Liu J, Yu C and Liu
A: Efficacy and safety of nab-paclitaxel as second-line
chemotherapy for locally advanced and metastatic non-small cell
lung cancer. Anticancer Res. 37:4687–4691. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Nakao A, Uchino J, Igata F, On R, Ikeda T,
Yatsugi H, Hirano R, Sasaki T, Tanimura K, Imabayashi T, et al:
Nab-paclitaxel maintenance therapy following carboplatin +
nab-paclitaxel combination therapy in chemotherapy naive patients
with advanced non-small cell lung cancer: Multicenter, open-label,
single-arm phase II trial. Invest New Drugs. 36:903–910.
2018.PubMed/NCBI View Article : Google Scholar
|
